Burkitt's Lymphoma, High-grade B-cell Lymphoma
Conditions
Brief summary
This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.
Detailed description
Inclusion criteria 1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria 2. age \>20 yrs 3. received rituximab+chemotherapy as first-line treatment 4. with measurable or evaluable lesion 5. with complete set of clinical and laboratory data for the analysis
Interventions
OTHERNo intervention (observational study)
Sponsors
Gachon University Gil Medical Center
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. pathologically confirmed Burkitt's lymphoma (BL) or High grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL (BL-U) by WHO 2008 criteria 2. age \>20 yrs 3. received rituximab+chemotherapy as first-line treatment 4. with measurable or evaluable lesion
Exclusion criteria
1\. patients with BL or BL-U previously treated with rituximab
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival | one year | Event-free survival is measured from the time from treatment initiation to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| complete response rate | 1-year | treatment response will be evaluated according to the Revised criteria for malignant lymphoma (Journal of Clinical Oncology 25:579-586) |
| overall survival | 1-year | Overall survival is defined as the time from treatment initiation until death as a result of any cause |
| Grade 4 hematologic toxicities | one year | toxicities will be graded according to Common Toxicity Criteria for Adverse Events (CTCAE) V.4.0. Hematologic toxicities planned to evaluated were; anemia (by hemoglobin), absolute neutrophil count, and platelet count |
Countries
South Korea
Outcome results
None listed